Personalized Medicine

Personalized Medicine bridges the gap between the latest advancements in genomics, genetics, and other related fields and their application in clinical practice. This journal serves as a collaborative space for a diverse group of stakeholders, including academic and clinical researchers, pharmaceutical firms, regulatory bodies, healthcare management organizations, patient advocacy groups, and others within the healthcare sector. By offering a platform for expert opinions and in-depth analysis, Personalized Medicine helps these stakeholders influence the evolution of medical practices. The journal covers a variety of topics related to precision medicine, tackling scientific, commercial, and policy aspects. It features articles that provide insights on emerging biomarkers, succinct commentary, conference reports, and comprehensive review articles. All submissions to Personalized Medicine undergo a thorough peer review process to ensure quality and credibility.

International, Trade/B2B

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#7320098

United States

#2791382

Health/Medicine

#9975

Traffic sources

Monthly visitors

Articles

Improving resource allocation in the precision medicine Era: a simulation-based approach using R | Personalized Medicine

May 16, 2024 | futuremedicine.com | Mohamed Kamal |Mohamed Nagy |Omneya Hassanain

The application of personalized medicine in developing countries is a major challenge, especially for those with poor economic status. A critical factor in improving the application of personalized medicine is the efficient allocation of resources. In healthcare systems, optimizing resource allocation without compromising patient care is paramount. This tutorial employs a simulation-based approach to evaluate the efficiency of bed allocation within a hospital setting.
Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy

May 5, 2024 | futuremedicine.com | Di Jiang |Abhijat Kitchlu |Launay-Vacher V |Richard T O'Dwyer

RT O'Dwyer has received support for travel and attending meetings from Pfizer and research funding from EMD Serono. DM Jiang has received research funding from Amgen, Tersera, and Astellas Pharma; honoraria from Janssen Oncology, Ipsen, Bayer, EMD Serono, Amgen, and AstraZeneca; consulting fees from Bayer, Pfizer, EMD Serono, McKesson, AstraZeneca, Merck, Janssen Oncology, and Novartis AAA; and support for attending meetings from EMD Serono. A Kitchlu administers funding from Amgen and Janssen.
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact® survey 2021

May 2, 2024 | futuremedicine.com | Laura Durbin |Bhavna Murali |Stephanie Hawthorne |Otávio Clark

Lung cancer is the most common form of cancer in China, with approximately 900,000 new cases diagnosed each year [1]. It is also the deadliest cancer in this country, with approximately 24% of all cancer deaths in China attributed to lung cancer [2].
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary

May 2, 2024 | futuremedicine.com | Emma Guttman-Yassky |Laura Brooks |Ken Clark |Lila Bahadori

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsWe thank the patients and their caregivers, as well as the study investigators and site staff, for participating in this study. We thank Olivia Fulton for providing feedback on the readability of this publication.
A review: cellular attachment and entry factors of human tumor-associated viruses

Apr 30, 2024 | futuremedicine.com | Yan Zhang |Bing Luo

Papers of special note have been highlighted as:• of interest; •• of considerable interest• None , Viral causality of human cancer and potential roles of human endogenous retroviruses in the multi-omics era: an evolutionary epidemiology review . ;11:687631. doi: . English. • A total of seven viruses have been found to cause tumors in humans. ;11:687631. doi:. English. • A total of seven viruses have been found to cause tumors in humans.
Nanomaterial-based drug-delivery system as an aid to antimicrobial photodynamic therapy in treating oral biofilm

Apr 29, 2024 | futuremedicine.com | Guanwen Sun |Shan Huang |Shaofeng Wang |Yijun Li

Supplemental Materials MetricsHistory Received 16 November 2023 Accepted 1 February 2024 Published online 29 April 2024 Information © 2024 Expert Publishing Medicine Ltd trading as Taylor & Francis KeywordsSupplementary data To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fmb-2023-0259 Author contributions Y Li and G Sun contributed to the conception and design of the study and wrote the first draft of the...
Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin

Apr 29, 2024 | futuremedicine.com | Xiang Zhang |Qi Yuan |Dawei Zhang

Background: This study investigated the influence of ADRB1 gene rs1801253 polymorphism on the treatment response of ticagrelor and aspirin in patients with acute coronary syndrome (ACS). Methods: Genetic typing was detected by Sanger sequencing. Platelet inhibition was assessed using thromboelastography. Kaplan–Meier and Cox regression were applied for prognosis analysis. Results: Out of 200 participants, 94 cases with rs1801253-CC genotype and 106 cases with CG+GG genotype were found.
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

Apr 10, 2024 | futuremedicine.com | Amin Haiderali |Min Huang |Wilbur Pan |Katherine G. Akers

Breast cancer is the most common cancer in women, with 2.3 million new cases worldwide in 2020 [1]. A subtype of breast cancer, triple-negative breast cancer (TNBC) accounts for ∼15% of all breast cancer cases and is characterized by the lack of ER, PR and HER2 [2]. TNBC has the worst prognosis among all breast cancer subtypes, with a median overall survival (OS) of 13 months in patients with metastatic TNBC compared with 38 months in patients with other types of breast cancer [3].
Nonseizure- and seizure-related benefits of cannabidiol treatment in the real world: plain language summary of the results from a caregiver survey

Apr 5, 2024 | futuremedicine.com | Anne T. Berg |Tracy Dixon-Salazar |Mary Anne Meskis |Sherry Danese

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThe authors would like to thank the participants of this survey for their valuable time and help. Financial disclosureThe survey was sponsored by Jazz Pharmaceuticals, Inc (formerly GW Pharmaceuticals companies), Palo Alto, CA, USA.
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen | Future Oncology

Mar 28, 2024 | futuremedicine.com | Jeremy Abramson |Scott Solomon |Jon Arnason |Patrick Johnston

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThe authors of this article thank the people who participated in this study and their families, as well as the investigators, co-investigators, and clinical site staff. Financial disclosureThe TRANSFORM study was sponsored by Celgene, a Bristol-Myers Squibb Company.